| Identification | Back Directory | [Name]
Benzonitrile, 4-[2,3-dihydro-7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl]-3-fluoro- | [CAS]
1360628-91-6 | [Synonyms]
4-[2,3-Dihydro-7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl]-3-fluorobenzonitrile
Benzonitrile, 4-[2,3-dihydro-7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1H-imidazo[4,5-c]quinolin-1-yl]-3-fluoro- | [Molecular Formula]
C23H17FN6O2 | [MOL File]
1360628-91-6.mol | [Molecular Weight]
428.42 |
| Chemical Properties | Back Directory | [Boiling point ]
634.8±65.0 °C(Predicted) | [density ]
1.41±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
5.36±0.20(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C23H17FN6O2/c1-28-12-14(10-27-28)15-7-16-18(8-21(15)32-3)26-11-20-22(16)30(23(31)29(20)2)19-5-4-13(9-25)6-17(19)24/h4-8,10-12H,1-3H3 | [InChIKey]
OOCGUVCGJIUQKC-UHFFFAOYSA-N | [SMILES]
C(#N)C1=CC=C(N2C3C4C(N=CC=3N(C)C2=O)=CC(OC)=C(C2=CN(C)N=C2)C=4)C(F)=C1 |
| Hazard Information | Back Directory | [Description]
M3541 is a potent, selective, orally active ATM inhibitor with potential chemo-/radio-sensitizing and antineoplastic activities. M-3541 targets and binds to ATM, thereby inhibiting the kinase activity of ATM and ATM-mediated signaling. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, induces tumor cell apoptosis, and leads to cell death of ATM-overexpressing tumor cells. In addition, M 3541 sensitizes tumor cells to chemo- and radiotherapy. ATM, a serine/threonine protein kinase, is upregulated in a variety of cancer cell types; it is activated in response to DNA damage and plays a key role in DNA-strand repair. | [Uses]
M3541 is a potent, ATP-competitive and selective ATM inhibitor with an IC50 of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities[1]. | [References]
[1] Astrid Zimmermann, et al. A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies. Mol Cancer Ther. 2022 Jun 1;21(6):859-870. DOI:10.1158/1535-7163.MCT-21-0934 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|